BAX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.82B

+2.57%

0.535

-7.84%

2.64B

+0.41%

0.498

-9.38%

2.84B

+1.05%

0.568

+5.1%

Estimates Revision

The market is revising Downward the revenue expectations for Baxter International Inc. (BAX) for FY2025, with the revenue forecasts being adjusted by -2.1% over the past three months. During the same period, the stock price has changed by -6.40%.

Revenue Estimates for FY2025

Revise Downward

-2.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.31%

In Past 3 Month

Stock Price

Go Down

-6.40%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 23.67 USD with a low forecast of 19.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

7 Hold

1 Sell

Hold

Current: 0.000

Low

19.00

Averages

23.67

High

36.00

Current: 0.000

Low

19.00

Averages

23.67

High

36.00

Goldman Sachs

Neutral

maintain

$22 -> $23

2026-01-09

New

Reason

Goldman Sachs

Price Target

$22 -> $23

2026-01-09

New

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on Baxter to $23 from $22 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Evercore ISI

Vijay Kumar

Outperform

downgrade

$24 -> $23

2026-01-05

New

Reason

Evercore ISI

Vijay Kumar

Price Target

$24 -> $23

2026-01-05

New

downgrade

Outperform

Reason

Evercore ISI analyst Vijay Kumar lowered the firm's price target on Baxter to $23 from $24 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Citi

Neutral

maintain

$21

2025-12-11

Reason

Citi

Price Target

$21

2025-12-11

maintain

Neutral

Reason

Citi opens an "upside 90-day catalyst watch" on Baxter while keeping a Neutral rating on the shares with a $21 price target. The firm sees the upcoming guidance from new management as a "clearing event."

Morgan Stanley

Patrick Wood

Underweight

downgrade

$19 -> $15

2025-12-02

Reason

Morgan Stanley

Patrick Wood

Price Target

$19 -> $15

2025-12-02

downgrade

Underweight

Reason

Morgan Stanley analyst Patrick Wood lowered the firm's price target on Baxter to $15 from $19 and keeps an Underweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.

Goldman Sachs

David Roman

Neutral

downgrade

$25 -> $22

2025-10-31

Reason

Goldman Sachs

David Roman

Price Target

$25 -> $22

2025-10-31

downgrade

Neutral

Reason

Goldman Sachs analyst David Roman lowered the firm's price target on Baxter to $22 from $25 and keeps a Neutral rating on the shares. Total sales of $2.84B came in slightly below guidance and consensus, with shortfalls across all segments, most notably in MPT and Pharma, the analyst tells investors in a research note. Gross margins declined sharply to 39.4%, pressured by manufacturing variances expected to persist into 4Q25 and early 2026, though lower R&D and SG&A spending partially offset the impact. Management reduced FY25 organic growth and EPS guidance to 1%-2% and $2.35-$2.40, respectively, implying near-term softness and limited visibility into 2026, where earnings headwinds are expected to outweigh tailwinds, the firm says.

Argus

Steve Silver

Buy

Hold

downgrade

2025-10-31

Reason

Argus

Steve Silver

Price Target

2025-10-31

downgrade

Buy

Hold

Reason

Argus analyst Steve Silver downgraded Baxter to Hold from Buy.

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 8.86, compared to its 5-year average forward P/E of 15.59. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

15.59

Current PE

8.86

Overvalued PE

19.81

Undervalued PE

11.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.92

Current EV/EBITDA

9.08

Overvalued EV/EBITDA

13.91

Undervalued EV/EBITDA

9.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.83

Current PS

0.90

Overvalued PS

2.58

Undervalued PS

1.08

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BAX News & Events

Events Timeline

No data

News

1.0

01-06Businesswire

Baxter to Present at J.P. Morgan 2026 Healthcare Conference on January 12, 2026

7.0

2025-12-16Globenewswire

Baxter International Faces Investigation Over Alleged Device Defects Impacting Patient Safety

7.0

2025-12-15Globenewswire

Baxter Faces Class Action Over Pump Defects with Deadline on December 15

People Also Watch

Frequently Asked Questions

What is Baxter International Inc (BAX) stock price today?

The current price of BAX is 21.07 USD — it has increased 1.84 % in the last trading day.

What is Baxter International Inc (BAX)'s business?

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

What is the price predicton of BAX Stock?

What is Baxter International Inc (BAX)'s revenue for the last quarter?

Baxter International Inc revenue for the last quarter amounts to 2.84B USD, increased 5.04 % YoY.

What is Baxter International Inc (BAX)'s earnings per share (EPS) for the last quarter?

Baxter International Inc. EPS for the last quarter amounts to -0.09 USD, decreased -133.33 % YoY.

What changes have occurred in the market's expectations for Baxter International Inc (BAX)'s fundamentals?

How many employees does Baxter International Inc (BAX). have?

Baxter International Inc (BAX) has 38000 emplpoyees as of January 10 2026.

What is Baxter International Inc (BAX) market cap?

Today BAX has the market capitalization of 10.83B USD.